Abstract
Background and Objectives
Although lipid-based drug delivery systems have gained much importance in recent years due to their ability to improve the solubility and bioavailability of poorly soluble drugs, compartmental pharmacokinetic analyses have not been extensively explored. The oral pharmacokinetics of commercial liquid formulation and a developed semisolid system containing saquinavir mesylate (SQVM) were compared in Beagle dogs. A compartmental analysis after intravenous bolus administration of this drug (1 mg/kg) was also performed.
Method
Pharmacokinetic profiles were analyzed using both non-compartmental and compartmental approaches. Plasma concentration of the drug was determined by high-performance liquid chromatography/tandem mass spectrometry (LC/MS/MS).
Results
The disposition curve of SQVM given intravenously was better described by a three-compartment model. In contrast, plasma profiles obtained following the oral administration were fitted to a two-compartment model with lag time due to the fact that the distribution phase was masked by the absorption phase in these formulations.
Conclusion
The proposed semisolid lipid system was found to be a promising formulation for commercial purposes given the similarity of SQVM absorption rate to that from the commercial liquid formulation.
References
Thomas N, Holm R, Mullertz A, Rades T. In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS). J Control Release. 2012;160(1):25–32.
Mu H, Holm R, Müllertz A. Lipid-based formulations for oral administration of poorly water-soluble drugs. Int J Pharm. 2013;453(1):215–24.
Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release. 2008;129(1):1–10.
Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. Eur J Pharm Sci. 2000;11(Suppl 2):S93–8.
Guiard-Schmid JB, Poirier JM, Meynard JL, Bonnard P, Gbadoe AH, Amiel C, et al. High variability of plasma drug concentrations in dual protease inhibitor regimens. Antimicrob Agents Chemother. 2003;47(3):986–90.
Caon T, Konig RA, da Cruz AC, Cardoso SG, Campos CE, Cuffini SL, et al. Development and physicochemical characterization of saquinavir mesylate solid dispersions using Gelucire 44/14 or PEG 4000 as carrier. Arch Pharm Res. 2013;36(9):1113–25.
Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW. Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res. 1992;9(1):87–93.
Neervannan S. Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin Drug Metab Toxicol. 2006;2(5):715–31.
Tam-Zaman N, Tam YK, Tawfik S, Wiltshire H. Factors responsible for the variability of saquinavir absorption: studies using an instrumented dog model. Pharm Res. 2004;21(3):436–42.
Caon T, Kratz JM, Kuminek G, Heller M, Konig RA, Micke GA, et al. Oral saquinavir mesylate solid dispersions: in vitro dissolution, Caco-2 cell model permeability and in vivo absorption studies. Powder Technol. 2015;269:200–6.
Craig DQM. Polyethyelene glycols and drug release. Drug Dev Ind Pharm. 1990;16(17):2501–26.
Lunn DJ, Aarons L. The pharmacokinetics of saquinavir: a Markov chain Monte Carlo population analysis. J Pharmacokinet Biopharm. 1998;26(1):47–74.
Zack JZ, Forrest A, Okusanya OO, Rosenkranz S, Para MF, Adams E, et al. Compartmental analysis of saquinavir (SQV) pharmacokinetics (PK). Clin Pharmacol Ther. 2005;77(2):P79-P.
Staats DA, Fisher JW, Connolly RB. Gastrointestinal absorption of xenobiotics in physiologically based pharmacokinetic models. A two-compartment description. Drug Metab Dispos. 1991;19(1):144–8.
Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliver Rev. 1997;25(1):103–28.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This study was supported by FAPESC/CNPq/MS/SES-SC (Grant Number 15.949/2009-2) and CAPES/MEC (Nanobiotechnology Network, Grant Number 759/2009).
Conflict of interest
TC, JMK, GK, MH, GAM, BVA, LSK and CMOS declare no conflicts of interest.
Ethical approval
The in vivo study protocol was approved by the Animal Ethics Committee of University of Santa Catarina.
Rights and permissions
About this article
Cite this article
Caon, T., Kratz, J.M., Kuminek, G. et al. Pharmacokinetics of Saquinavir Mesylate from Oral Self-Emulsifying Lipid-Based Delivery Systems. Eur J Drug Metab Pharmacokinet 42, 135–141 (2017). https://doi.org/10.1007/s13318-016-0321-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-016-0321-x